Drug Database
Back to search

Czechia· CZ-0250514

PEMAZYRE

A pemigatinib product containing pemigatinib, registered in Czechia by Incyte Biosciences Distribution B.V., Amsterdam. The same ATC class is registered in 14 of our 19 countries.

ATC L01EN02

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedPEMAZYREATCL01EN02REGISTER NO.CZ-0250514PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pemigatinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pemigatinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EN02 (pemigatinib), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose
Search pemigatinib products by name

Pemigatinib · ATC L01EN02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pemigatinib costs, country by country.

Normalised to the WHO defined daily dose (9 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Pemigatinib · price per daily dose (9 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1227.26
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
PEMIGATINIB
Manufacturer
Incyte Biosciences Distribution B.V., Amsterdam
Country
Czechia (CZ)
ATC code
L01EN02
ATC class
Pemigatinib
Defined daily dose
9 mg, O
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0250514
    14
    CZK 175788.73

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

71 interactions on record for pemigatinib.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pemigatinib against other medicinesHow interaction checks work

Pemigatinib · interactions on record

71 records

  • 30 severe
  • 41 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ChloramphenicolJ01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pemigatinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pemigatinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pemazyre
  • Liechtenstein · Pemazyre
  • Norway · Pemazyre

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ba9fe6d0-236b-4785-a8ca-dfd5253836c7
GET /v1/drugs/ba9fe6d0-236b-4785-a8ca-dfd5253836c7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "TBL NOB",
  "source": "sukl",
  "strength": "13,5MG",
  "pack_size": "14",
  "substance": "PEMIGATINIB",
  "cz_kod_sukl": "0250514",
  "product_type": "CH",
  "substance_codes": "21804",
  "registration_state": "R",
  "registration_number": "EU/1/21/1535/005"
}
API referenceMCP serverPlans

See everything about pemigatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console